Gb Sciences, Inc. has been issued a new patent by the U.S. Patent and Trademark Office (USPTO) for a cannabinoid-containing mixture designed to treat cardiac hypertrophy, often present in advanced heart disease. Gb Sciences' newly issued patent also covers the use of these receptor-targeted formulations for the treatment of TRPV1-receptor-associated hearing loss and urinary cystitis. Despite multiple categories of prescription heart medications on the market, heart disease remains the leading cause of death in the United States for people of most racial and ethnic groups.

Alternative therapeutic approaches are still needed, especially for the treatment of advanced heart disease.